{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-177317","form_type":"8-K/A","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.199392+00:00","generated_at":"2026-05-15T04:11:18.693515+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AnaptysBio pro forma continuing ops net income $114.9M after First Tracks spin-off","bullets":["Pro forma continuing ops net income $114.9M for FY2025; basic EPS $3.99, diluted $3.07.","Collaboration revenue $234.6M, operating income $217.9M after spin-off adjustments.","AnaptysBio provided $100M cash distribution to First Tracks; expects $7M non-recurring costs within 12 months.","Pro forma balance sheet as of Dec 31, 2025 shows negative stockholders' equity of $116.3M.","First Tracks shares began trading on Nasdaq under ticker TRAX on April 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-177317","json":"https://secwatch.observer/filing/0001193125-26-177317.json","markdown":"https://secwatch.observer/filing/0001193125-26-177317.md","text":"https://secwatch.observer/filing/0001193125-26-177317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526177317/0001193125-26-177317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526177317/d104779d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:11:18.693515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}